

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<p>(51) International Patent Classification <sup>7</sup> : C12N 15/62, 15/86, 15/12, 5/10, 1/21, I/19, C07K 14/705, A61K 39/00, 31/713, G01N 33/50</p>	<p>A1</p>	<p>(11) International Publication Number: <b>WO 00/15807</b></p>
<p>(21) International Application Number: PCT/DK99/00481</p> <p>(22) International Filing Date: 13 September 1999 (13.09.99)</p>		<p>(43) International Publication Date: 23 March 2000 (23.03.00)</p>
<p>(30) Priority Data: PA 1998 01164 15 September 1998 (15.09.98) DK 60/102,896 2 October 1998 (02.10.98) US</p>		<p>(81) Designated States: AE, AL, AM, AT, AT (Utility model), AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, CZ (Utility model), DE, DE (Utility model), DK, DK (Utility model), DM, EE, EE (Utility model), ES, FI, FI (Utility model), GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SK (Utility model), SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).</p>
<p>(71) Applicant (for all designated States except US): M &amp; E BIOTECH A/S [DK/DK]; Kogle Allé 6, DK-2970 Hørsholm (DK).</p> <p>(72) Inventors; and (73) Inventors/Applicants (for US only): HAAKIER, Torben [DK/DK]; Hestkøvej 11 E, DK-3460 Birkerød (DK). HAANING, Jesper [DK/DK]; Biskop Svanes Vej 2E, DK-3460 Birkerød (DK).</p> <p>(74) Agent: KOEFOED, Peter; M &amp; E Biotech A/S, Kogle Allé 6, DK-2970 Hørsholm (DK).</p>		
<p>(54) Title: METHOD FOR DOWN-REGULATING OSTEOPROTEGERIN LIGAND ACTIVITY</p>		
<p>(57) Abstract</p> <p>The invention provides a novel method for down-regulating the biological activity of osteoprotegerin ligand (OPGL, TRANCE) thereby rendering possible the treatment/amelioration of diseases characterized by excessive loss of bone mass, e.g. osteoporosis. Down-regulation is effected by inducing an immune response against OPGL in an individual in need thereof. Immune responses can be raised by classical immunization with immunogenic variants of OPGL or by nucleic acid immunization where the nucleic acids encode the OPGL variant. The invention also pertains to compositions, polypeptides and nucleic acids useful in the invention, as well as to vectors and transformed host cells useful in the preparation thereof.</p>		

09787126-031401